Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Conclusion In a large database capturing a heterogeneous patient population and varied treatment patterns reflecting routine clinical care, we found a clinical benefit of continued longer DOT at first relapse. Despite the emerging paradigm favoring continuous therapy, second-line PFS (proxied by TTNT) was over 2-fold longer than DOT. Understanding barriers to extended duration of therapy may help improve outcomes in RRMM. Teaser Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting in duration of therapy that is significantly shorter than time to next therapy. We further describe the association between length of therapy in second line and improved overall survival in patients with relapsed/refractory multiple myeloma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research